Physician profile
John S Fried
NPI 1689752909
$7,283.15
in general payments reported to CMS, 2019-2025
44 companies · $822 in 2025
The $822 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $624 · 2021: $1,156 · 2022: $1,313 · 2023: $1,214 · 2024: $984 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.17 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,824.09 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $1,340.03 | 2019-2025 | Pifeltro, Dificid, Zerbaxa |
| Gilead Sciences, INC. | $848.30 | 2019-2025 | Biktarvy, Descovy |
| Insmed, INC. | $559.34 | 2019-2025 | Brinsupri, Arikayce |
| Abbvie INC. | $532.22 | 2022-2025 | |
| Organogenesis INC. | $505.91 | 2019-2025 | Puraply, Apligraf |
| Melinta Therapeutics, LLC | $283.66 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Smith+Nephew, INC. | $197.59 | 2019-2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.81 | 2019-2024 | |
| Shionogi INC | $113.83 | 2022 | |
| Integra Lifesciences Corporation | $82.83 | 2025 | Tcc-Ez |
| Amgen INC. | $73.39 | 2020-2024 | Prolia, Evenity |
| Paratek Pharmaceuticals, INC. | $70.70 | 2024-2025 | Nuzyra |
| Next Science LLC | $61.81 | 2023-2024 | Surgx, Xperience, Blastx |
| Bayer Healthcare Pharmaceuticals INC. | $52.23 | 2021-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.